{
    "clinical_study": {
        "@rank": "60265", 
        "acronym": "STEPWISE", 
        "arm_group": [
            {
                "arm_group_label": "CLP", 
                "arm_group_type": "Experimental", 
                "description": "CLP BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "BID powder"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a placebo-controlled study to determine the effect of CLP in heart failure subjects\n      with fluid overload."
        }, 
        "brief_title": "Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Selected Inclusion Criteria:\n\n          -  Age 21 years or older at randomization\n\n          -  Heart failure with at least one of the following signs of current fluid overload:\n\n               1. Peripheral (or sacral) edema >1+ or ascites during screening or on day of\n                  randomization\n\n               2. Pulmonary congestion as determined by chest X-ray during the screening period\n\n          -  Ambulatory and able to perform the 6-minute walk test\n\n        Selected Exclusion Criteria:\n\n          -  Participation in another clinical trial of an investigational or marketed drug within\n             30 days or 5 half-lives (whichever is longer) preceding screening\n\n          -  Any hospitalization or unscheduled outpatient decongestion therapy using IV\n             diuretics, ultrafiltration, or paracentesis within 8 weeks prior to or during\n             screening\n\n          -  Coronary-artery bypass graft, percutaneous intervention (e.g., cardiac,\n             cerebrovascular, aortic), or major surgery including thoracic and cardiac, within 2\n             months prior to or during screening or anticipated need during study participation\n\n          -  Heart transplant recipient, or anticipated need for transplant or LVAD during study\n             participation\n\n          -  Any of the following events having occurred within 8 weeks prior to or during\n             screening: myocardial infarction, transient ischemic attack, stroke, or acute\n             coronary syndrome as judged by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736735", 
            "org_study_id": "CTST-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "CLP", 
                "intervention_name": "CLP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tustin", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92780"
                    }, 
                    "name": "Orange Country Research Center"
                }, 
                "investigator": {
                    "last_name": "Joel Neutel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ashkelon", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Israel"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects", 
        "overall_contact": {
            "email": "jadebrennan@momentum-research.com", 
            "last_name": "Jade Brennan", 
            "phone": "919-491-5721"
        }, 
        "overall_contact_backup": {
            "email": "jchang@sorbent.com", 
            "last_name": "Jean Chang"
        }, 
        "overall_official": {
            "affiliation": "Sorbent Therapeutics, Study Sponsor", 
            "last_name": "Howard Dittrich, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite endpoint for the change from baseline to 8 weeks comprised of the following:  6-Minute Walk Test (6 MWT), Body weight, KCCQ Score, Log2 NT-proBNP, time to first occurrence of heart failure or renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart failure or renal failure, or death.", 
            "measure": "Composite endpoint comprised of: 6-Minute Walk Test, Body weight, KCCQ Score, Log2 NT-proBNP, time to first occurrence of heart/renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart/renal failure or death", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 8"
        }, 
        "removed_countries": {
            "country": "Russian Federation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736735"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in 6-Minute Walk Test distance from baseline to Week 8.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }, 
            {
                "measure": "Time to heart failure or renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart failure or renal failure, or death", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Sorbent Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sorbent Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}